In this video, Sean P. Elliott, MD, MS, FACS, discusses the abstract, “Interim results for the ROBUST III trial evaluating the Optilume drug-coated balloon for anterior urethral strictures,” which was presented during the 2021 American Urological Association annual meeting. Elliott is a professor, vice chair of urology, and director of reconstructive urology at the University of Minnesota, Minneapolis.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.